Eli Lilly Achieves 80% Jump In COVID-19 Therapy Sales, Revises FY22 Guidance

Loading...
Loading...
  • Eli Lilly And Co LLY has posted Q1 sales of $7.8 billion, beating the consensus of $6.68 billion.
  • Lilly's revenue increased 15%, driven by volume growth of 20%, partially offset by a 3% decrease due to lower realized prices and a 2% decrease due to the unfavorable impact of foreign exchange rates. 
  • Excluding revenue from COVID-19 antibodies and Alimta, Q1 2022 revenue grew 10%.
  • Key growth products, consisting of Trulicity, Verzenio, Jardiance, Taltz, Olumiant, Emgality, Retevmo, Cyramza, and Tyvyt, contributed 13 percentage points of revenue growth.
  • Trulicity sales jumped 20% to $1.74 billion.
  • Revenue from COVID-19 antibodies reached $1.47 billion compared with $810.1 million in Q1 2021.
  • The adjusted gross margin was 76.1%, an increase of 0.7 percentage points from a year ago. The adjusted operating margin reached 33.4%.
  • Adjusted EPS increased 63% Y/Y to $2.62, ahead of the consensus of $2.13.
  • FY22 guidance: Eli Lilly anticipates revenue of $28.8 billion - $29.3 billion, better than the earlier outlook of $27.8 billion - $28.3 billion, compared to the consensus of $24.88 billion.
  • The guidance reflects additional COVID-19 antibodies revenue from selling 600,000 doses of bebtelovimab to the U.S. government in Q1 2022.
  • Lilly sees adjusted EPS as $8.15 - $8.30, down from prior guidance of $8.50 - $8.65, versus the consensus of $8.19.
  • Price Action: LLY shares are up 2.66% at $292.67 during the market session on the last check Thursday.
Loading...
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...